[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596426":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":36,"centralContacts":40,"locations":46,"responsibleParty":60,"collaborators":63,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":44,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":44,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":95,"whyStopped":44,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Emory University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"POC glucose meter with Blinded CGM (Control\u002Fstandard of care)","ACTIVE_COMPARATOR","Participants in the standard-of-care study arm will be provided with a Bluetooth-enabled blood glucose (BG) meter and testing supplies. A blood glucose monitoring account will be established and linked to the research site. Participants will be asked to perform glucose testing from 1- 3x daily. Testing would involve a minimum of once-daily tests that should include random fasting and post-prandial measurements. All participants will also be wearing blinded CGM devices. Providers will adjust oral agents or insulin doses based on POC results.",[13],"Diagnostic Test: POC BG + Blinded CGM",{"label":15,"type":16,"description":17,"interventionNames":18},"Real Time CGM (RT-CGM)","EXPERIMENTAL","Participants in the CGM group will wear a Libre 2 rt-CGM with hypoglycemia and hyperglycemia alarms, and providers will adjust insulin therapy based on CGM profile information. All participants will be instructed on CGM placement and care. Diabetes educators will provide training sessions in the CGM system. The diabetes educator will educate subjects on how the CGM system differs from the traditional blood glucose (BG) meter",[19],"Device: Libre 2 rt-CGM",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Libre 2 rt-CGM","Freestyle Libre 2 consists of a sensor applied to the back of the upper arm. The sensor is a penny-sized flexible filament placed beneath the skin's surface to measure interstitial fluid. This sensor is applied utilizing a sensor applicator provided in the packaging. The sensor continuously reads interstitial glucose readings every minute and syncs with the Freestyle View app. The hypoglycemia alarm will be set to \\\u003C 80 mg\u002Fdl (for prevention of low blood glucose levels). Participants will be instructed to provide 15 grams of carbohydrates in response to a hypoglycemia alarm. The hyperglycemia alarm will be set at 300 mg\u002Fdl. Participants will call the research team if they experience repeated episodes \\> 300 mg\u002Fdl (more than 2 episodes in a single day or 2 or more episodes in consecutive days). The research team will instruct the participant to check with their physician for a possible new insulin regimen, but they will be allowed to remain in the study.",[15],[27,28],"FreeStyle Libre Pro Glucose Monitoring System","Continuous Glucose Monitoring (CGM) device",{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DIAGNOSTIC_TEST","POC BG + Blinded CGM","Standard of care point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the study participation for up to 3 months.",[9],[35],"Standard of care capillary glucose test and blinded CGM",[37],{"name":38,"affiliation":5,"role":39},"Kasra Moazzami, MD, MPH","PRINCIPAL_INVESTIGATOR",[41],{"name":38,"role":42,"phone":43,"phoneExt":44,"email":45},"CONTACT","404- 616-1000",null,"kasra.moazzami@emory.edu",[47],{"facility":48,"status":44,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":44},"Grady Health System","Atlanta","Georgia","30303","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-84.38798,33.749,{"lat":58,"lon":57},{"type":39,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"Kasra Moazzami","Assistant Professor",[64,66],{"name":65,"class":6},"American Heart Association",{"name":67,"class":68},"Abbott Diabetes Care","INDUSTRY","100596426","cgm-use-in-heart-failure-100596426",false,"NCT07045298","CGM Use in Heart Failure","Real-Time Continuous Glucose Monitoring for the Management of Patients With Type 2 Diabetes and Acutely Decompensated Heart Failure","Inclusion Criteria:\n\n* Adults 18 to 90 years admitted with a diagnosis of acute decompensated heart failure (ADHF), New York Heart Association (NYHA) class II, III, or IV symptoms (Aim 1) and discharged with a clinical diagnosis of ADHF (Aim 2).\n* Patients with diabetes treated with diet alone or oral antidiabetic agents, Glucagon-like peptide-1 receptor agonists (GLP1-RAs), or insulin after discharge\n\nExclusion Criteria:\n\n* Age \\\u003C 18 or \\> 90 years;\n* Patients with a history of type 1 diabetes;\n* Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study;\n* Patients on ventricular assist devices;\n* History of a heart transplant or listed for a heart transplant;\n* History of cardiac surgery (within 90 days before enrollment) or planned cardiac interventions within the following 6 months;\n* Female participants who are pregnant or breastfeeding at the time of enrollment into the study;\n* Hospice care or expected life expectancy of less than 6 months;\n* Patients who are expected to require Magnetic Resonance Imaging (MRI) procedures during hospitalization or after discharge.","ALL","18 Years","90 Years",{"count":80,"type":81},140,"ESTIMATED","INTERVENTIONAL",[84],"NA","Heart failure (HF) is a major cause of hospital admissions in the US, with over 6 million hospital days annually.\n\nMore than 40% of hospitalized patients with HF have diabetes mellitus (DM), which increases the risk of recurrent hospitalizations for HF with reduced and preserved ejection fraction by more than two-fold. Current methods for assessing glycemic control do not consider fluctuations in blood glucose levels, known as glycemic variability. High glycemic variability is a poor prognostic marker for HF re-hospitalizations. Given the significant prevalence and impact of DM in individuals with HF, it is crucial to examine whether improving glycemic control and avoiding hypoglycemia could lead to a decrease in HF readmissions. Real-time continuous glucose monitoring (rt-CGM), which provides glucose measurements as frequently as every 5 minutes, has improved glycemic control in insulin-treated adults with DM compared to the standard of care, capillary point-of-care blood glucose testing (POC). Researchers will monitor participants during their hospital stay and 3 months after discharge.",[87,88],"Heart Failure","Diabetes Mellitus",[90,91,92,93,94],"Continuous Glucose Monitoring (CGM) system","Acute Decompensated Heart failure","Glycemic control","Inpatient","Bedside point-of-care capillary glucose monitoring","NOT_YET_RECRUITING","2026-07-21",{"date":98,"type":99},"2026-07-22","ACTUAL",{"date":101,"type":81},"2026-11",{"date":103,"type":81},"2027-11",{"name":5,"class":6},1]